This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Baxter International Inc.
Drug Names(s): Nexterone Premixed Injection, PM101, Captisol-enabled amiodarone hydrochloride
Description: Nexterone is a novel intravenous formulation of amiodarone that incorporates CyDex's patented Captisol technology
Amiodarone is an antiarrhythmic agent used for various types of tachyarrhythmias, both ventricular and supraventricular (atrial) arrhythmias, but its precise mechanism of action is unknown. It is primarily a class III antiarrhythmic, but also has class I, II, and IV effects. Among other things, it slows conduction and prolongs the refractoriness of tissue to a new electrical impulse. The specific currents/receptors it blocks are: INa, ICaL, ICaT, IKr, Iks, IKATP, IKAch, If, and beta1R. There may be differences in some electrophysiological effects between IV and oral formulations.
Deal Structure: Nexterone was developed by CyDex.
In early 2006, CyDex licensed worldwide rights to Nexterone to Prism Pharmaceuticals. CyDex is eligible to receive milestones, royalties, and Captisol material sales revenue from this program.
In January 2011, Ligand acquired CyDex Pharmaceuticals.
In April 2011, Baxter International announced that it has entered into a definitive agreement to acquire Prism Pharmaceuticals for total considerations of up to $338 million. The acquisition was completed in May 2011.
Partners: Ligand Pharmaceuticals, Inc.
Additional information available to subscribers only: